Publication | Closed Access

Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial

Her2-overexpressing Stage IiOncologyBreast OncologyBreast CancerCancer TreatmentIii Breast CancerMedicineRadiation Oncology